Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker SLXNW
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Sep 28, 2026 | SCHEDULE 13D/A (amended) | SLXN Silexion Therapeutics Corp | Ilan Levin | 1.95M | 17.7% | SCHEDULE 13D/A ↗ |
| Sep 28, 2026 | SCHEDULE 13D/A (amended) | SLXN Silexion Therapeutics Corp | Moringa Partners Ltd | 1.95M | 17.7% | SCHEDULE 13D/A ↗ |
| Sep 28, 2026 | SCHEDULE 13D/A (amended) | SLXN Silexion Therapeutics Corp | Moringa Sponsor, LP | 1.95M | 17.7% | SCHEDULE 13D/A ↗ |
| Aug 19, 2026 | SCHEDULE 13D/A (amended) | SLXN Silexion Therapeutics Corp | Ilan Levin | 1.39M | 10.6% | SCHEDULE 13D/A ↗ |
| Aug 19, 2026 | SCHEDULE 13D/A (amended) | SLXN Silexion Therapeutics Corp | Moringa Partners Ltd | 1.39M | 10.6% | SCHEDULE 13D/A ↗ |
| Aug 19, 2026 | SCHEDULE 13D/A (amended) | SLXN Silexion Therapeutics Corp | Moringa Sponsor, LP | 1.39M | 25.0% | SCHEDULE 13D/A ↗ |
| Aug 18, 2026 | SCHEDULE 13G | SLXN Silexion Therapeutics Corp | Intracoastal Capital LLC | 286,866 | 5.0% | SCHEDULE 13G ↗ |
| Aug 18, 2026 | SCHEDULE 13G | SLXN Silexion Therapeutics Corp | Daniel B. Asher | 286,866 | 5.0% | SCHEDULE 13G ↗ |
| Aug 18, 2026 | SCHEDULE 13G | SLXN Silexion Therapeutics Corp | Mitchell P. Kopin | 286,866 | 5.0% | SCHEDULE 13G ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | SLXN Silexion Therapeutics Corp | Intracoastal Capital LLC | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | SLXN Silexion Therapeutics Corp | Daniel B. Asher | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | SLXN Silexion Therapeutics Corp | Mitchell P. Kopin | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Jun 23, 2026 | SCHEDULE 13D/A (amended) | SLXN Silexion Therapeutics Corp | Ilan Levin | 199,053 | 10.6% | SCHEDULE 13D/A ↗ |
| Jun 23, 2026 | SCHEDULE 13D/A (amended) | SLXN Silexion Therapeutics Corp | Moringa Partners Ltd | 199,053 | 10.6% | SCHEDULE 13D/A ↗ |
| Jun 23, 2026 | SCHEDULE 13D/A (amended) | SLXN Silexion Therapeutics Corp | Moringa Sponsor, LP | 199,053 | 10.6% | SCHEDULE 13D/A ↗ |
| May 29, 2026 | SCHEDULE 13D/A (amended) | SLXN Silexion Therapeutics Corp | Ilan Levin | 1.38M | 33.0% | SCHEDULE 13D/A ↗ |
| May 29, 2026 | SCHEDULE 13D/A (amended) | SLXN Silexion Therapeutics Corp | Moringa Partners Ltd | 1.38M | 33.0% | SCHEDULE 13D/A ↗ |
| May 29, 2026 | SCHEDULE 13D/A (amended) | SLXN Silexion Therapeutics Corp | Moringa Sponsor, LP | 1.38M | 33.0% | SCHEDULE 13D/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | SLXN Silexion Therapeutics Corp | Jeff Easton | 212,500 | 5.0% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | SLXN Silexion Therapeutics Corp | Lind Global Partners III LLC | 212,500 | 5.0% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | SLXN Silexion Therapeutics Corp | Lind Global Fund III LP | 212,500 | 5.0% | SCHEDULE 13G/A ↗ |
| Feb 13, 2026 | SCHEDULE 13G/A (amended) | SLXN Silexion Therapeutics Corp | Intracoastal Capital LLC | 325,000 | 9.4% | SCHEDULE 13G/A ↗ |
| Feb 13, 2026 | SCHEDULE 13G/A (amended) | SLXN Silexion Therapeutics Corp | Daniel B. Asher | 325,000 | 9.4% | SCHEDULE 13G/A ↗ |
| Feb 13, 2026 | SCHEDULE 13G/A (amended) | SLXN Silexion Therapeutics Corp | Mitchell P. Kopin | 325,000 | 9.4% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | SLXN Silexion Therapeutics Corp | Jeff Easton | 212,500 | 6.4% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | SLXN Silexion Therapeutics Corp | Lind Global Partners III LLC | 212,500 | 6.4% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | SLXN Silexion Therapeutics Corp | Lind Global Fund III LP | 212,500 | 6.4% | SCHEDULE 13G/A ↗ |
| Sep 23, 2025 | SCHEDULE 13D/A (amended) | SLXN Silexion Therapeutics Corp | Ilan Levin | 458,824 | 14.7% | SCHEDULE 13D/A ↗ |
| Sep 23, 2025 | SCHEDULE 13D/A (amended) | SLXN Silexion Therapeutics Corp | Moringa Partners Ltd | 458,824 | 14.7% | SCHEDULE 13D/A ↗ |
| Sep 23, 2025 | SCHEDULE 13D/A (amended) | SLXN Silexion Therapeutics Corp | Moringa Sponsor, LP | 457,342 | 14.6% | SCHEDULE 13D/A ↗ |
| Sep 18, 2025 | SCHEDULE 13G | SLXN Silexion Therapeutics Corp | Jeff Easton | 224,050 | 9.9% | SCHEDULE 13G ↗ |
| Sep 18, 2025 | SCHEDULE 13G | SLXN Silexion Therapeutics Corp | Lind Global Partners III LLC | 224,050 | 9.9% | SCHEDULE 13G ↗ |
| Sep 18, 2025 | SCHEDULE 13G | SLXN Silexion Therapeutics Corp | Lind Global Fund III LP | 224,050 | 9.9% | SCHEDULE 13G ↗ |
| Sep 17, 2025 | SCHEDULE 13G | SLXN Silexion Therapeutics Corp | Intracoastal Capital, LLC | 244,771 | 10.0% | SCHEDULE 13G ↗ |
| Sep 17, 2025 | SCHEDULE 13G | SLXN Silexion Therapeutics Corp | Daniel B. Asher | 244,771 | 10.0% | SCHEDULE 13G ↗ |
| Sep 17, 2025 | SCHEDULE 13G | SLXN Silexion Therapeutics Corp | Mitchell P. Kopin | 244,771 | 10.0% | SCHEDULE 13G ↗ |
| Sep 15, 2025 | SCHEDULE 13G/A (amended) | SLXN Silexion Therapeutics Corp | Orca Capital AG | 109,432 | 4.9% | SCHEDULE 13G/A ↗ |
| Sep 15, 2025 | SCHEDULE 13G | SLXN Silexion Therapeutics Corp | Orca Capital AG | 131,250 | 6.2% | SCHEDULE 13G ↗ |
| Sep 15, 2025 | SCHEDULE 13G | SLXN Silexion Therapeutics Corp | Lincoln Alternative Strategies LLC | 131,250 | 6.2% | SCHEDULE 13G ↗ |
| Jun 26, 2025 | SCHEDULE 13D/A (amended) | SLXN Silexion Therapeutics Corp | Leonard A. Potter | 113,428 | 1.3% | SCHEDULE 13D/A ↗ |
| Jun 26, 2025 | SCHEDULE 13D/A (amended) | SLXN Silexion Therapeutics Corp | Wildcat Partner Holdings, LP | 113,428 | 1.3% | SCHEDULE 13D/A ↗ |
| Jun 26, 2025 | SCHEDULE 13D/A (amended) | SLXN Silexion Therapeutics Corp | Wildcat Capital Management, LLC | 113,428 | 1.3% | SCHEDULE 13D/A ↗ |
| May 13, 2025 | SCHEDULE 13G/A (amended) | SLXN Silexion Therapeutics Corp | Goldman Sachs & Co. LLC | 211,945 | 2.4% | SCHEDULE 13G/A ↗ |
| May 13, 2025 | SCHEDULE 13G/A (amended) | SLXN Silexion Therapeutics Corp | The Goldman Sachs Group, Inc. | 211,945 | 2.4% | SCHEDULE 13G/A ↗ |
| May 12, 2025 | SCHEDULE 13G/A (amended) | SLXN Silexion Therapeutics Corp | Heights Capital Management, Inc. | 456,531 | 4.9% | SCHEDULE 13G/A ↗ |
| May 12, 2025 | SCHEDULE 13G/A (amended) | SLXN Silexion Therapeutics Corp | CVI Investments, Inc. | 456,531 | 4.9% | SCHEDULE 13G/A ↗ |
| Feb 10, 2025 | SCHEDULE 13G | SLXN Silexion Therapeutics Corp | Goldman Sachs & Co. LLC | 112,242 | 6.6% | SCHEDULE 13G ↗ |
| Feb 10, 2025 | SCHEDULE 13G | SLXN Silexion Therapeutics Corp | The Goldman Sachs Group, Inc. | 112,242 | 6.6% | SCHEDULE 13G ↗ |
| Jan 23, 2025 | SCHEDULE 13G | SLXN Silexion Therapeutics Corp | Heights Capital Management, Inc. | 339,000 | 8.5% | SCHEDULE 13G ↗ |
| Jan 23, 2025 | SCHEDULE 13G | SLXN Silexion Therapeutics Corp | CVI Investments, Inc. | 339,000 | 8.5% | SCHEDULE 13G ↗ |
Full history on every feed is part of Premium. Premium loads older rows, up to 10,000, and CSV downloads.
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 6:47 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances